SUWON, Republic of Korea, September 24, 2021 (GLOBE NEWSWIRE) – OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapies, today announced that the company will present new data on its entire pipeline at the Oligonucleotide Therapeutics Society Virtual Conference 2021, which will be held virtually from September 26 to 29, 2021.
Key data includes the results of preclinical studies for its investigational treatment targeting hepatitis B virus (HBV) and OLX702A, an investigational RNAi-based treatment for the treatment of non-alcoholic steatohepatitis (NASH). OliX previously announced that OLX702A reversed tissue damage in the liver in a mouse model of NASH.
OliX will also present an overview of its pipeline OLX101A for hypertrophic scars, OLX104C for hair loss, OLX301A / D for age-related macular degeneration and subretinal fibrosis. The Company plans to launch clinical trials for OLX104C and OLX301A / D in 2022.
The titles of the pre-recorded poster presentations are below:
GalNAc-conjugated RNAi Therapeutics by OliX Pharmaceuticals (2021-P-236-OTS) Development of asymmetric cell-penetrating siRNA therapies targeting skin diseases, hypertrophic scars and androgenetic alopecia Associated macular degeneration (2021-P242-OTS) RIG-I mediated innate immune stimulation by chemically synthesized long double-stranded RNAs is structure and sequence dependent (2021-P-224-OTS)
About OliX Pharmaceuticals
OliX Pharmaceuticals is a clinical-stage pharmaceutical company that develops therapies for a variety of disorders by down-regulating the expression of pathogenic genes, based on its own proprietary RNAi technology. The Company’s main RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered to be the most efficient gene silencing technology. Based on asiRNA technology, OliX has developed cell-penetrating asiRNAs (cp-asiRNA), a therapeutic RNAi platform to effectively target locally administered diseases, such as hypertrophic scar, age-related macular degeneration (AMD) ) wet and dry, subretinal fibrosis, idiopathic lung disease. fibrosis (IPF) and neuropathic pain. OliX has also developed another RNAi therapeutic platform, GalNAc-asiRNA, to target various liver diseases. For more information, please visit: https://www.olixpharma.com/fra
Jon Yu Westwicke / ICR PR Phone: +1.475.395.5375 [email protected]
Copyright 2021 GlobeNewswire, Inc.